Previous studies | Antibodies | Ovary benign mucinous tumours | Ovary benign/borderline mucinous tumours | Ovary mucinous carcinomas |
---|---|---|---|---|
Bowen et al19 | α-mPax8-bIII,pAb* | ND | ND | 2/18 |
Nonaka et al14 | RpAb† | ND | ND | 1/12 |
Köbel et al22 | α-mPax8-bIII,pAb* | ND | ND | 2/31 |
Tabrizi et al21 | pAb* | ND | ND | 0/30 |
Laury et al15 | RpAb† | ND | ND | 10/25 |
Tong et al29 | RpAb† | ND | ND | 0/2 |
Tacha et al18 | RpAb‡ | 0/1 | ND | 27/54 |
Ozcan et al13 | RpAb† | ND | 6/31 | 2/9 |
Chu et al20 | RpAb§ | ND | ND | 9/19 |
Liliac et al23 | RpAb† | ND | ND | 4/13 |
Total (%) | 0/1(0) | 6/31 (19.4) | 57/213 (26.76) |
*Non-commercial.
†Proteintech Group Inc.
‡Biocare Medical.
§Cell Marque.
ND, not done; pAb, polyclonal antibody; RpAb, recombinant polyclonal antibody.